Protocol Ledger

NCT07089888 · Phase III · RECRUITING

A Study of Dotinurad Versus Allopurinol in Tophaceous Gout

Interventional Phase III clinical trial protocol NCT07089888 sponsored by Crystalys Therapeutics in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-08-04 Enrollment: 250 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07089888
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)250 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07089888
Protocol FieldVerified Registry Value
NCT IdentifierNCT07089888
Consolidated Lead SponsorCrystalys Therapeutics
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment250 participants (ESTIMATED)
Registered Start Date2025-08-04
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI